DGI:Opportunistische Infektionen/Invasive Aspergillose/Quellen - Revision history

imported>Bestem at 16:18, 30 November 2021

2021-11-30T16:18:24Z

Show changes

imported>Bestem at 13:50, 24 November 2021

2021-11-24T13:50:27Z

Show changes

imported>Bestem at 13:50, 24 November 2021

2021-11-24T13:50:07Z

Show changes

imported>Bestem at 13:49, 24 November 2021

2021-11-24T13:49:44Z

Show changes

imported>Bestem at 13:26, 24 November 2021

2021-11-24T13:26:55Z

← Older revision		Revision as of 13:26, 24 November 2021
Line 9:		Line 9:
	[[Datei:DGI:3.png\|mini\|'''Abbildung 1B''' – EQUAL Aspergillosis Score 2018<ref name=":0" /><sup><span style="mso-no-proof:yes">29</span></sup>]]		[[Datei:DGI:3.png\|mini\|'''Abbildung 1B''' – EQUAL Aspergillosis Score 2018<ref name=":0" /><sup><span style="mso-no-proof:yes">29</span></sup>]]
	<br />		<br />

			# Sivak-Callcott JA, Livesley N, Nugent RA, Rasmussen SL, Saeed P, Rootman J. Localised invasive sino-orbital aspergillosis: characteristic features. Br J Ophthalmol. 2004;88(5):681-687. doi:10.1136/bjo.2003.021725
			# Fernández-Ruiz M, Silva JT, San-Juan R, et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore). 2012;91(5):261-273. doi:10.1097/MD.0b013e31826c2ccf
			# Machida U, Kami M, Kanda Y, et al. Aspergillus tracheobronchitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;24(10):1145-1149. doi:10.1038/sj.bmt.1702030
			# van Assen S, Bootsma GP, Verweij PE, Donnelly JP, Raemakers JM. Aspergillus tracheobronchitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;26(10):1131-1132. doi:10.1038/sj.bmt.1702679
			# Segal BH. Aspergillosis. N Engl J Med. 2009;360(18):1870-1884. doi:10.1056/NEJMra0808853
			# Lambourne J, Agranoff D, Herbrecht R, et al. Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2009;49(10):1486-1491. doi:10.1086/644619
			# Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med. 2014;370(5):421-432. doi:10.1056/NEJMoa1211161
			# Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. 2008;359(17):1766-1777. doi:10.1056/NEJMoa0802629
			# Cunha C, Di Ianni M, Bozza S, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 2010; 116(24): 5394-402.
			# Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34(7): 909-17.
			# Schauwvlieghe A, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. The Lancet Respiratory medicine 2018; 6(10): 782-92.
			# Koehler P, Cornely OA, Bottiger BW, et al. COVID-19 associated pulmonary aspergillosis. Mycoses 2020; 63(6): 528-34.
			# ??
			# Koehler P, Cornely OA, Bottiger BW, et al. COVID-19 associated pulmonary aspergillosis. Mycoses 2020; 63(6): 528-34
			# Schauwvlieghe A, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. The Lancet Respiratory medicine 2018; 6(10): 782-92
			# Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(7):909-917. doi:10.1086/339202.
			# Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39(5): 743-6.
			# Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350(9): 950-2.
			# Maschmeyer G, Patterson TF. Our 2014 approach to breakthrough invasive fungal infections. Mycoses 2014; 57(11): 645-51.
			# Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408-15.
			# Cornely OA, Koehler P, Arenz D, S CM. EQUAL Aspergillosis Score 2018: An ECMM score derived from current guidelines to measure QUALity of the clinical management of invasive pulmonary aspergillosis. Mycoses 2018; 61(11): 833-6.
			# Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Annals of internal medicine 2015; 162(2): 81-9.
			# Patterson TF, Thompson GR, 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63(4): e1-e60.
			# Mousset S, Buchheidt D, Heinz W, et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of hematology 2014; 93(1): 13-32.
			# Koehler P, Cornely OA. Contemporary Strategies in the Prevention and Management of Fungal Infections. Infectious disease clinics of North America 2016; 30(1): 265-75.
			# Verweij PE, Ananda-Rajah M, Andes D, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2015; 21-22: 30-40
			# 38. Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42(12): 1859-64.
			# 39. Steinbach WJ, Benjamin DK, Jr., Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39(2): 192-8.
			# Balajee SA, Nickle D, Varga J, Marr KA. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryotic cell 2006; 5(10): 1705-12.
			# Vinh DC, Shea YR, Sugui JA, et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis 2009; 49(1): 102-11.
			# Hamprecht A, Buchheidt D, Vehreschild JJ, et al. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill 2012; 17(36): 20262.
			# Steinmann J, Hamprecht A, Vehreschild MJ, et al. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother 2015; 70(5): 1522-6.
			# van Paassen J, Russcher A, In 't Veld-van Wingerden AW, Verweij PE, Kuijper EJ. Emerging aspergillosis by azole-resistant Aspergillus fumigatus at an intensive care unit in the Netherlands, 2010 to 2013. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2016; 21(30).
			# Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS medicine 2008; 5(11): e219.
			# Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS medicine 2008; 5(11): e219.
			# van der Linden JW, Camps SM, Kampinga GA, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013; 57(4): 513-20.
			# van der Linden JW, Jansen RR, Bresters D, et al. Azole-resistant central nervous system aspergillosis. Clin Infect Dis 2009; 48(8): 1111-3.
			# Koehler P, Hamprecht A, Bader O, et al. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. International journal of antimicrobial agents 2017; 49(2): 218-23.
			# Cornely OA, Koehler P, Arenz D, C Mellinghoff S. EQUAL Aspergillosis Score 2018: An ECMM score derived from current guidelines to measure QUALity of the clinical management of invasive pulmonary aspergillosis. Mycoses. 2018;61(11):833-836. doi:10.1111/myc.12820

imported>Bestem: Bestem verschob die Seite DGI:Invasive Aspergillose/Quellen nach DGI:Opportunistische Infektionen/Invasive Aspergillose/Quellen

2021-11-24T07:15:24Z

Bestem verschob die Seite DGI:Invasive Aspergillose/Quellen nach DGI:Opportunistische Infektionen/Invasive Aspergillose/Quellen

← Older revision	Revision as of 07:15, 24 November 2021
(No difference)

imported>Bestem at 17:40, 7 November 2021

2021-11-07T17:40:42Z

← Older revision		Revision as of 17:40, 7 November 2021
Line 9:		Line 9:
	[[Datei:DGI:3.png\|mini\|'''Abbildung 1B''' – EQUAL Aspergillosis Score 2018<ref name=":0" /><sup><span style="mso-no-proof:yes">29</span></sup>]]		[[Datei:DGI:3.png\|mini\|'''Abbildung 1B''' – EQUAL Aspergillosis Score 2018<ref name=":0" /><sup><span style="mso-no-proof:yes">29</span></sup>]]
	<br />		<br />
	~~<references />~~

imported>Bestem at 17:40, 7 November 2021

2021-11-07T17:40:33Z

← Older revision		Revision as of 17:40, 7 November 2021
Line 6:		Line 6:
	https://www.ecmm.info/equal-scores/ - Diagnose und Therapiescores der ECMM.		https://www.ecmm.info/equal-scores/ - Diagnose und Therapiescores der ECMM.
	<br />		<br />
	[[Datei:DGI:1.png\|mini\|'''Abbildung 1A''' – EQUAL Aspergillosis Score 2018<sup><span style="mso-no-proof:yes">29</span></sup><ref name=":0"~~><span style="font-size:11.0pt;line-height:107%;~~		[[Datei:DGI:1.png\|mini\|'''Abbildung 1A''' – EQUAL Aspergillosis Score 2018<sup><span style="mso-no-proof:yes">29</span></sup><ref name=":0">Cornely OA, Koehler P, Arenz D, C Mellinghoff S. EQUAL Aspergillosis Score 2018: An ECMM score derived from current guidelines to measure QUALity of the clinical management of invasive pulmonary aspergillosis. Mycoses. 2018;61(11):833-836. doi:10.1111/myc.12820</ref>]]
	~~font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:~~
	~~Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;~~
	~~mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;mso-ansi-language:~~
	~~DE;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">29. <span style="mso-tab-count:1"> </span~~>Cornely OA, Koehler P, Arenz D, S CM. EQUAL Aspergillosis Score 2018: An ECMM score derived from current guidelines to measure QUALity of the clinical management of invasive pulmonary aspergillosis. ''Mycoses'' 2018; ~~'''~~61~~'''~~(11): 833-6.</~~span>~~</ref>]]
	[[Datei:DGI:3.png\|mini\|'''Abbildung 1B''' – EQUAL Aspergillosis Score 2018<ref name=":0" /><sup><span style="mso-no-proof:yes">29</span></sup>]]		[[Datei:DGI:3.png\|mini\|'''Abbildung 1B''' – EQUAL Aspergillosis Score 2018<ref name=":0" /><sup><span style="mso-no-proof:yes">29</span></sup>]]
	<br />		<br />
			<references />

imported>Bestem at 10:58, 16 January 2021

2021-01-16T10:58:36Z

← Older revision		Revision as of 10:58, 16 January 2021
Line 5:		Line 5:

	https://www.ecmm.info/equal-scores/ - Diagnose und Therapiescores der ECMM.		https://www.ecmm.info/equal-scores/ - Diagnose und Therapiescores der ECMM.
			<br />
			[[Datei:DGI:1.png\|mini\|'''Abbildung 1A''' – EQUAL Aspergillosis Score 2018<sup><span style="mso-no-proof:yes">29</span></sup><ref name=":0"><span style="font-size:11.0pt;line-height:107%;
			font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:
			Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;
			mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;mso-ansi-language:
			DE;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">29. <span style="mso-tab-count:1"> </span>Cornely OA, Koehler P, Arenz D, S CM. EQUAL Aspergillosis Score 2018: An ECMM score derived from current guidelines to measure QUALity of the clinical management of invasive pulmonary aspergillosis. ''Mycoses'' 2018; '''61'''(11): 833-6.</span></ref>]]
			[[Datei:DGI:3.png\|mini\|'''Abbildung 1B''' – EQUAL Aspergillosis Score 2018<ref name=":0" /><sup><span style="mso-no-proof:yes">29</span></sup>]]
			<br />

imported>Bestem at 10:31, 16 January 2021

2021-01-16T10:31:06Z

← Older revision		Revision as of 10:31, 16 January 2021
Line 1:		Line 1:
	== Weiterführende Literatur und Hilfestelllungen ==		==Weiterführende Literatur und Hilfestelllungen==
	[http://www.ecmm.info www.ecmm.info] – Homepage der European Confederation of Medical Mycolcogy.https://www.ecmm.info/ecmm-excellence-centers/ - Kennzeichnung der Excellenzzentren der ECMM.		[http://www.ecmm.info www.ecmm.info] – Homepage der European Confederation of Medical Mycolcogy.

			https://www.ecmm.info/ecmm-excellence-centers/ - Kennzeichnung der Excellenzzentren der ECMM.

	https://www.ecmm.info/equal-scores/ - Diagnose und Therapiescores der ECMM.		https://www.ecmm.info/equal-scores/ - Diagnose und Therapiescores der ECMM.